I'm leading a project to develop a new mRNA vaccine against COVID-19. Can you walk me through the current status of the clinical trials? I'd like to discuss the manufacturing process further, specifically focusing on the cell culture step and how it relates to the production timeline for our vaccine. Can you provide an overview of the regulatory landscape for mRNA vaccines in the EU, including information on the authorization process for any relevant reports or documents that may have been submitted by other companies in the industry. Additionally, can you summarize the key takeaways from the recent FDA meeting on mRNA vaccines and provide more context on why the agency has been hesitant to approve mRNA-based vaccines in the past? Were there any specific concerns about their stability or safety profile? Can you also recommend a course of action for us to take in response to these developments and how we might be able to mitigate any potential risks to our company's interests? Finally, I'd like to discuss the patent landscape for mRNA technology and whether our competitor's application has been granted. If so, what implications this might have for our company's competitive position and how can we prepare for potential challenges from other companies in the industry. Can you provide more details on the current status of your company's mRNA vaccine development program and any upcoming milestones or deadlines that we should be aware of? Specifically, I'm interested in knowing if there are any planned clinical trials or regulatory submissions scheduled for the next 6-12 months and how these might impact our company's pipeline and competitive position. Can you also summarize the key differences between your company's mRNA vaccine technology and ours, including any unique features or advantages that set us apart from the competition? Finally, can you provide more context on why your company has been hesitant to engage in public discussions about the safety and efficacy of mRNA-based vaccines? Were there any specific concerns or issues that led to this approach, and how do you think we might be able to build trust with regulatory agencies and other stakeholders in the industry? If so, can you recommend a course of action for us to take in response to these developments and how we might be able to mitigate any potential risks to our company's interests? In terms of next steps, I'd like to schedule a follow-up meeting with your team to discuss these topics in more detail. Can you provide me with some suggested dates and times for our meeting, as well as any other relevant information or materials that we should review before our discussion?